S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

AMRN Amarin Corp PLC

0.4401

-0.0079 (-1.76%)

Dec 30 2024 - Closed

Delayed by 15 minutes

Form 3 - Initial statement of beneficial ownership of securities

Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more Amarin Charts.

Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more Amarin Charts.

Amarin Corp PLC News

Form 8-K - Current report
Wednesday 18 December 2024 (2 weeks ago) • Edgar (US Regulatory)

Amarin Receives National Reimbursement for VAZKEPA® in Italy
Monday 16 December 2024 (2 weeks ago) • GlobeNewswire Inc.

Amarin Appoints Peter Fishman Chief Financial Officer
Friday 13 December 2024 (2 weeks ago) • GlobeNewswire Inc.

Form 8-K - Current report
Friday 22 November 2024 (1 month ago) • Edgar (US Regulatory)

Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual
Monday 11 November 2024 (2 months ago) • GlobeNewswire Inc.

Form 3 - Initial statement of beneficial ownership of securities
Thursday 31 October 2024 (2 months ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 30 October 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 30 October 2024 (2 months ago) • Edgar (US Regulatory)

Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update
Wednesday 30 October 2024 (2 months ago) • GlobeNewswire Inc.

Amarin Announces Two Upcoming Investor Events
Tuesday 1 October 2024 (3 months ago) • GlobeNewswire Inc.

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe
Monday 9 September 2024 (4 months ago) • GlobeNewswire Inc.

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
Thursday 22 August 2024 (4 months ago) • GlobeNewswire Inc.

More Amarin Corp PLC News Articles

Invesco Us High Yield Fa...

Vontobel Financial Produ...

Kingdom of Belgium

VinaCapital Vietnam Oppo...

SG Issuer Societe Generale

JPMorgan BetaBuilders Ch...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions